Introduction

Metabolic Associated Steatotic Liver Disease (MASLD) affects 25-30% of the European population and is projected to rise further. These patients are at increased risk for liver-related complications and higher overall mortality, emphasizing the need for early detection to improve outcomes. While abdominal ultrasound serves as the primary imaging modality for suspected liver disease, its sensitivity for diagnosing mild steatosis is inadequate, and gold-standard methods for quantifying liver steatosis infiltration, such as magnetic resonance imaging or liver biopsy are impractical for widespread use.

Aims & Methods

This study aimed to assess the diagnostic accuracy of the Attenuation Coefficient (ATT) as a complementary method to B-mode ultrasound for early detection of hepatic steatosis. Consecutive patients referred for transient elastography were prospectively enrolled. Liver steatosis was graded using a 4-point scale (normal, mild, moderate, or severe) in B-mode ultrasound for each patient, and ATT was measured in accordance with manufacturer quality criteria instructions (Fujifilm®). Additionally, the Hepato-Renal Index (HRI) was calculated for each patient, and Controlled Attenuation Parameter (CAP, Fibroscan®) was measured.

Results

A total of 128 patients, 61.7% male, with a mean age of 56.8±12.8 years, were included. Among them, 78.1% exhibited at least one cardiometabolic risk factor. The main referral indications were fibrosis assessment in viral hepatitis (42.2%), MASLD (21.9%), and alcoholic liver disease (11.7%). The median vibration-controlled elastography result was 5.8kPa. B-mode ultrasound steatosis assessment classified 44.5% as normal, 10.2% with mild steatosis, 21.1% with moderate steatosis, and 24.2% with severe steatosis. The area under the ROC curve for steatosis detection was 0.796 for HRI, 0.894 for ATT, and 0.896 for CAP, highlighting robust diagnostic performance, particularly for the latter two methods. There was a strong correlation between ATT and CAP (r=0.710). Using a CAP>248dB/m to define steatosis, the area under the ROC curve for ATT was 0.890. For an ATT cutoff value ≥0.66, Sensitivity, Specificity, Negative Predictive Value, and Positive Predictive Value were 82.7%, 77.3%, 72.3%, and 86.1%, respectively. The sensitivity of B-mode ultrasound for steatosis detection was 79.5%, increasing to 90.4% when combined with ATT measurement.

Conclusion

ATT demonstrated excellent accuracy for steatosis detection, comparable to CAP and superior to HRI. Importantly, combining B-mode ultrasound with ATT significantly improved the diagnostic sensitivity. These findings suggest that ATT has the potential to become a valuable non-invasive tool alongside ultrasound for early detection of hepatic steatosis, aiding in earlier intervention and improved patient outcomes.

References

Tamaki N, Koizumi Y, Hirooka M, et al. Novel quantitative assessment system of liver steatosis using a newly developed attenuation measurement method. Hepatol Res. 2018;48(10):821-828. doi:10.1111/hepr.13179
Bozic D, Podrug K, Mikolasevic I, Grgurevic I. Ultrasound Methods for the Assessment of Liver Steatosis: A Critical Appraisal. Diagnostics. 2022;12(10):2287. doi:10.3390/diagnostics12102287

Introduction

MACE is a new, non-invasive technology which approaches the diagnostic sensitivity of OGD in gastric focal lesion detection in patients with dyspepsia. [Li et al., CGH 2016] This study compared the two in the detection of focal and diffuse lesions in patients referred for the investigation of anaemia.

Aims & Methods

MACE was performed within one week before OGD using the AnX Robotica magnet system and Navicam capsule (single camera capsule, frame rate 6/sec: Wuhan, China). Following a fast, simethicone and gastric distension using 0.5-1L water, patients swallowed the capsule semi-recumbent on the left lateral side before lying supine to allow approximation of the magnet to the chest. The examination protocol included a sequence of magnet movements and patient position changes. Inspection of an anatomical location was considered complete if sufficient to exclude any significant pathology. Endoscopists performing OGD were blinded to the MACE outcome and all findings were recorded from a pre-identified diagnostic list. Data was analysed using SPSS.

Results

45 of 81 (55.5%; median age 63 (IQR 45.5- 72), 60% male) patients had pathology identified by MACE, OGD or both. Complete views were obtained by MACE in the oesophagus (72.4%), proximal stomach (93.8%), distal stomach (93.8%) and duodenum(79.6%, p<0.001) and mean examination time was 22 minutes. Findings were concordant in 17 (37.8%: gastric erosions (n=6), ulcers (n=5), oesophagitis (n=2), eroded polyps (n=2) and gastric antral vascular ectasia (n=2)). MACE alone identified pathology in 24 (53.3%: gastric erosions (n=17), angioectasia (n=4), ulcers (n=2, oesophageal and duodenal), eroded polyp (n=1) and both angioectasia and erosions (n=1). OGD identified a distal body ulcer (n=1), small (n=1) and large (n=1) oesophageal varices and oesophageal ulcers (n=1) missed by MACE and in one patient MACE identified only an oesophageal ulcer and OGD only a duodenal ulcer, each missing the pathology detected by the other. Diagnostic yield was higher for MACE than OGD (P<0.001).

Conclusion

The improved diagnostic yield of MACE compared to OGD is accounted for mainly by minor mucosal abnormalities which could, nonetheless, contribute to occult bleeding and anaemia. Although speculative this could be because of better tolerance of MACE and a longer examination time. An increased frame capture rate, with or without a second camera, is needed to improve oesophageal visualisation.

Disclosure

I herwith declare that the magnetic capsules for the study were provided by Ankon

Introduction

Patients with IBD often have related anxiety and depression which may negatively impact disease activity and have been consistently highlighted as an unmet need by patient groups. Timely access to psychiatric and psychological support can be difficult and costly. We investigated the effectiveness of a novel cognitive behavioural therapy (CBT) program delivered by a trained mental health nurse in place of a formal psychologist.

Aims & Methods

A retrospective review of all CBT referrals made for adult patents between Sep 2019 – Dec 2022 in a tertiary IBD Centre. Referrals were from IBD Consultants, senior medical Trainees, IBD Nurses and a liaison psychiatrist. Patients are offered high-intensity CBT for up to 8 consecutive weeks as per local protocol of a minimum 4 sessions. The CBT took place virtually; over the phone or video call via MS Teams. Patients who completed at least 4 sessions of CBT were included in this review.
Our primary measure was to assess if there was an improvement in mental health using CORE-10, a brief validated psychometric questionnaire, completed at the start and end of therapy. A score of greater than 11 was an indicator of psychological distress, and a reduction of 6 points is clinically meaningful[i].

Results

96 patients were referred to the inflammatory bowel disease CBT service. Of those 47 patients went on to complete at least 4 sessions of CBT, with an average age of 33. 91% of referrals were for either anxiety or depression. With other cited indications including; anger management, PTSD and functional pain.
15 patients (32%) had UC, 31 patients (66%) had Crohn’s disease and 1 patient had indeterminate colitis. The majority of patients had 8 sessions of CBT of which all were completed virtually. The average disease duration was least 8 years at the time of referral.
26 (55%) of patients were on biologics at the time of initiating CBT, with 23% patient of patients referred having undergone at least one surgery prior to referral. Physician global assessment at the initiation of CBT showed 25 (56%) patients were in clinical remission. 21 (45%) patients were in clinical remission following their course of CBT.
Following the completed CBT sessions 37 patients had some improvement in their CORE-10 score with a mean reduction for all patients of 7.6. 20 patients had a CORE-10 reduction of at least 6. 33 patients (70%) had a CORE10 score of >11 at baseline, indicating significant psychological distress. Of the 33 patients with an initial score >11, 20 patients 61% showed reliable clinical improvement.
10 patients (21%) referred for CBT showed, either an increase (8 patients) or no change (2 patients) in their CORE10 score following at least 4 sessions of CBT.

Conclusion

Studies have consistently demonstrated a high burden of anxiety amongst patients with IBD which can have a detrimental effect on quality of life and disease outcomes. CBT delivered by a trained mental health nurse is an effective and relatively low-cost intervention for patients with IBD, delivering beneficial treatment outcomes, and maintaining good levels of engagement; including those with a severe phenotype of disease.
CBT did not significantly influence disease activity as measured by physician global assessment.

References

[i] Barkham, M., Bewick, B., Mullin, T., Gilbody, S., Connell, J., Cahill, J., Mellor-Clark, J., Richards, D., Unsworth, G. and Evans, C. (2013b). The CORE-10: A short measure of psychological distress for routine use in the psychological therapies. Counselling and Psychotherapy Research, 13(1), pp.3–13. doi:https://doi.org/10.1080/14733145.2012.729069.

Disclosure

nil

Introduction

COVID-19, as a systemic disease, critically affects the liver and biliary system. Secondary sclerosing cholangitis (SSC) is an increasing complication in critically ill patients. After severe COVID-19 infection, the occurrence of bile duct changes resembling the picture of SSC has been increasingly observed. The early prognosis of COVID-19-associated SSC has not been adequately studied.

Aims & Methods

The aim of this study is to investigate the effects of COVID-19 on the liver in relation to previous hepatic disease, as well as to identify early prognostic markers for the course of disease in patients and the development of any complications. 261 patients treated in intensive care units of the University Hospital Regensburg and suffering from COVID-19 were analyzed in different groups. The classification was based on the presence and type of previous hepatic disease. Laboratory and clinical parameters collected during hospitalization included values at the time of admission and maximum values that developed during hospitalization. These were evaluated concerning mortality rates and the development of COVID-19-associated SSC in the different patient groups.

Results

Patients with pre-existing chronic liver disease had a hazard ratio for death of 2.045 (p=0.0446) compared to patients without chronic liver disease. The hazard ratio for death was higher for patients with pre-existing chronic liver disease than for patients with malignant disease (HR=1.986, p=0.0135) or dialysis requirement on ICU admission (HR=1.732, p=0.034). In all groups, mortality was also significantly correlated with an increase in liver enzymes during hospitalization. High bilirubin (p=0.002) or INR (p=0.018) levels on admission also correlated with increased mortality, independent of pre-existing hepatic disease. Among the entire cohort, the cause of death was associated with COVID-19 in 90.8%. In addition, the risk of developing COVID-19-associated SSC increased with the duration of ECMO therapy and correlated significantly (p=0.004) with high AP levels on admission.

Conclusion

This study demonstrates the potent effects of COVID-19 on the liver and biliary system and potential complications in patients with and without pre-existing chronic liver disease. Bilirubin and INR could serve as predictive factors for mortality. AP could be considered an early predictor for the development of COVID-19-associated SSC in patients with COVID-19. In the future, this will provide crucial clues for an optimized treatment strategy, including ventilation and sedation.

Introduction

Renal disorders are among the extra-intestinal manifestations of inflammatory bowel disease (IBD), and treatments may also lead to renal failure. However, the incidence of end-stage renal disease (ESRD), defined as the need for renal replacement therapy (dialysis and/or renal transplantation (RT)), is poorly known. The primary objective of our study was to assess the incidence of ESRD in IBD patients, and to compare it with the general health insurance scheme population.

Aims & Methods

We conducted a prognostic cohort study based on data from the French National Health Insurance Database(SNDS). Prevalent cases of IBD affiliated to the general health insurance scheme during the period 2011-2020 were identified on the basis of declarations long-term diseases ALD 24 or the presence of 2 hospital stays for IBD with ICD-10 codes or a single stay with reimbursement of specific treatments. Incident cases of ESRD were identified on the basis of a stay with a RT or a period with dialysis sessions for at least 45 days. Crude incidence rates of ESRD were calculated over the period for the IBD and the non-IBD population, with their 95% confidence intervals.

Results

A total of 280,283 IBD patients were included in the study over the period 2011-2020, 134,567 with ulcerative colitis(UC) and 145,716 with Crohn’s disease(CD). The mean age at study inclusion was 39.8 (± 17.1) years. The M/F sex ratio was 0.9. The mean age at incidence of ESRD in the non-IBD population was 65.0 (±17.0) years, the M/F sex ratio cases was 1.7.
Among IBD patients, 534 patients began replacement therapy by dialysis or RT, they were younger than non-IBD patients (60.3(±16.7)years, P<0.001).The mean incidence rate of ESRD over the period was 26.4 per 100,000 person-years (IC95% 23.1-29.6), 480 (89.9%) patients entered ESRD by dialysis, and 54 (10.1%) by preemptive RT. In the non-IBD population the mean rate of ESRD was 15.9 per 100,000 person-years (IC95% 14.8- 17.1; P<0.0001 compared with IBD): 79,606 (94.5%) patients entered ESRD by dialysis, and 4,634 (5.5%) by RT (as compared with IBD,P<0.001). In subgroup analysis, the mean incidence rate of ESRD was 22.8 per 100,000 person-years (IC95% 18.9-26.7) in UC patients and 29.5 (IC95% 25.3-33.6) in CD patients (P<0,0001). The rates of preemptive RT were 12.4% in UC patients (87.6% dialysis) and 8.6% in CD patients (91.4% dialysis).
Over a median follow-up of 6.8 years, the survival rate after ESRD was 40.8% in ESRD-IBD patients VS 34.2% in ESRD non-IBD patients (P<0.001). This difference remained significant for patients under 65 (p<0.0073).
No significant difference for the risk of re-hospitalization after RT (p=0.84), of retransplantation during the follow-up period in RT patients (p=0.67), or for the risk of hospitalization for severe infection (p=0.97) after RT in patients from the general population compared with IBD patients. The same was true for the type of severe infections after RT (p= 0.068) and for the risk of solid and haematological cancer after RT (p=0.48). However, there was a significant difference in the type of first severe infection after RT(p=0.003), but we are waiting for the results to tell us which one.

Conclusion

The incidence of ESRD is significantly higher in IBD than in the general data base population, confirming the need for regular monitoring of renal function in our patients.
Survival after ESRD onset, is higher in IBD patients.
The high incidence of RT in the IBD population confirms that access to transplantation is not restricted in this
population.

References

Kirchgesner et al, Gastroenterology 2018
Meyer et al, Aliment Pharmacol Ther. 2020
Tuppin et al, Nephrol Ther 2016

Introduction

Various endoscopic closure procedures including over-the-scope systems and endoscopic hand suturing have been tested in preventing delayed bleeding after endoscopic resection1). Conventional procedures are technically difficult with long procedure time1), which partially explains its limited application in clinical practice. The novel through-the-scope (TTS) helix and tack suture system has been reported with high success rates and acceptable procedure time using in vivo porcine models along with clinical experience2,3). However, past reports have not identified the proficiency rate of the TTS suture system.

Aims & Methods

The objective of this study is to determine the number of cases needed in achieving closure time of literature-based mean closure time. One beginner with less than 400 experiences of upper gastrointestinal endoscopy and one expert with clinical experience of over 500 endoscopic submucosal dissections participated in this study. Both endoscopists were familiarized with the functionality and troubleshooting of the novel TTS suture system via educational videos. Four in vivo porcine models were used to create 24 mucosal defects with diameter of 2-4 cm in the stomach. Each endoscopist were randomly allocated 12 mucosal defects to close with one set of TTS suture system per procedure. The TTS suture system engages four 5 mm helical tacks tethered to a suture thread into the defect margin and approximates the mucosal defect by applying suture tension with a cinch. The primary outcome was the number of procedures required to achieve closure procedure time below the literature-based mean closure time (7.7 minutes) by inverse curve fitting with nonlinear regression. The secondary outcomes were the success rate of complete closure and the incidence of adverse events. Complete closure was defined as over 90% closure of defect in endoscopy image assessed by two certified endoscopy technicians.

Results

Mean (±SD) size of the mucosal defects was 2.9 (±0.2) cm. Both endoscopists required six cases to achieve a closure time of less than 7.7 minutes. The median closure time was 8.2 (IQR: 5.6-10.1) minutes for the expert and 8.0 (IQR: 6.3-9.4) minutes for the beginner (P = 0.8624). The success rates of complete closure were 75.0% (9/12) for the expert and 83.3% (10/12) for the beginner. Neither endoscopist experienced any adverse events.

Conclusion

The novel TTS suture system requires a small number of cases for both expert and beginner to achieve proficiency in endoscopic closure.

References

1) Kobara H, et al. Dig Endosc. 2023;35(2):216-31.
2) Hernandez A, et al. Endosc Int Open. 2021;09:E572-7.
3) Farha J, et al. Endoscopy. Published online: 12 Jan 2023; doi:10.1055/a-1970-5528.

Introduction

Delayed bleeding (DB) is a possible adverse event following gastric endoscopic submucosal dissection (ESD). The Bleeding after ESD Trend from Japan (BEST-J) score was created as a risk prediction model for DB following gastric ESD, but is yet to be validated in non-Asiatic populations.

Aims & Methods

We aimed to apply and validate the BEST-J score on a European sample.
We have conducted a longitudinal study of all consecutive patients undergoing gastric ESD on a European Endoscopic Unit. DB was defined as a hemorrhage with clinical symptoms and confirmed by emergency endoscopy from the time of completion of ESD to 28 days after ESD.
BEST-J score (use of vitamin K antagonists +4, direct oral anticoagulants +4, aspirin or P2Y12R antagonists +2; withdrawing antithrombotic drugs -1; chronic kidney disease +3; multiple lesions +1; lesion ≥30mm +1; lesion in lower-third of the stomach +1) was calculated in each patient and confronted with the outcome (DB).

Results

Final sample included 161 patients, 102 (63.4%) male, with a mean age of 68±8 years. From these, 10 (6.2%) presented DB following ESD, with a median time to bleeding of 7 days (IQR 6.8).
According to BEST-J score, bleeding risk was low (0-1 points) in 111 (68.9%), intermediate (2 points) in 29 (18.0%), high (3-4 points) in 16 (9.9%) and very high (≥5 points) in 5 (3.1%) patients.
BEST-J score presented an excellent accuracy predicting DB in our sample, with an AUC=0.907 (95%CI=0.801-1.000; p<0.001). The optimal cut-off value to predict DB was a BEST-J score ≥3, which matches the cut-off value for high-risk of bleeding in the original investigation. This value had a sensitivity of 90% and specificity of 92%.

Conclusion

The BEST-J score still presents excellent accuracy in risk stratification for post-ESD bleeding in European individuals. Thus, this score may help to guide which patients benefit the most from prophylactic therapies following gastric ESD in this setting.